Researchers at Albert Einstein College of Medicine reported a manufacturing strategy using an engineered protein scaffold (HCW9206) that fuses IL‑7, IL‑15 and IL‑21 to generate CAR‑T cells enriched in long‑lived T memory stem cells. In preclinical mouse models the approach yielded CAR‑T populations with prolonged persistence and improved disease control versus standard activation protocols. The team published results in Science Advances showing the scaffold‑produced cells maintained robust effector function while generating a larger share of self‑renewing memory cells—an attribute linked to durable remissions in cell therapy. Translational work and clinical validation will determine whether the scaffold can be integrated into commercial CAR‑T manufacturing to reduce relapse rates and extend indications, including potential applications in HIV.